Common use of Terms of New Notes Clause in Contracts

Terms of New Notes. The New Notes are to be issued as Additional Notes under the Indenture and shall: a. be issued as part of the existing series of Existing Notes under the Indenture, and the New Notes and the Existing Notes shall be a single class for all purposes under the Indenture, including, without limitation, with respect to waivers, amendments, redemptions and offers to purchase; b. be issued at an issue price of 104.00%, plus accrued and unpaid interest from October 1, 2018 and will be issued on October 5, 2018; c. be issuable in whole in the form of one or more Global Notes to be issued in the name of Cede & Co. and held by the Trustee as Custodian for the Depositary and in the form, including appropriate transfer restriction legends, provided in Exhibit 1 to the Appendix to the Indenture; d. bear, in the case of New Notes sold under Rule 144A of the Securities Act, the CUSIP number of ▇▇▇▇▇▇▇▇▇ and ISIN of US665531AF68, and, in the case of New Notes sold under Regulation S of the Securities Act, initially bear the CUSIP number of ▇▇▇▇▇▇▇▇▇ and ISIN of USU66499AC57; e. bear interest from October 1, 2018, with a first Interest Payment Date of January 1, 2019; and f. be subject to a registration rights agreement dated October 5, 2018 relating to such Additional Notes, which shall be a “Registration Rights Agreement” for purposes under the Indenture.

Appears in 2 contracts

Sources: Second Supplemental Indenture (Northern Oil & Gas, Inc.), Second Supplemental Indenture

Terms of New Notes. The New Notes are to be issued as Additional Notes under the Indenture and pursuant to this Supplemental Indenture shall: a. A. be issued as part of the existing series of Existing Notes previously issued under the Indenture, Indenture and the New Notes and the Existing Notes shall be a single class for all purposes under the Indenture, including, without limitation, with respect to waivers, amendments, redemptions and offers to purchase; b. be issued at an issue price of 104.00%, plus accrued and unpaid interest from October 1, 2018 and will B. be issued on October 5July 14, 20182010 at a purchase price of 96.250% of the principal amount and will accrue interest from January 29, 2010; c. C. be issuable in whole in the form of one or more Global Notes to be issued in the name of Cede & Co. and held by the Trustee as Custodian for the Depositary Depository and in the form, including appropriate transfer restriction legends, provided in Exhibit 1 to the Appendix A1 and Exhibit A2, as applicable, to the Indenture; d. D. the New Notes shall initially bear, in the case of New Notes sold under Rule 144A of the Securities Act144A, the CUSIP number of ▇▇▇▇▇▇▇▇▇ 92203P AF3 and ISIN number of US665531AF68US92203PAF36, and, in the case of New Notes sold under Regulation S of the Securities Act, initially bear the CUSIP number of ▇▇▇▇▇▇▇▇▇ U92165 AC0 and ISIN number of USU66499AC57; e. bear interest from October 1, 2018, with a first Interest Payment Date of January 1, 2019USU92165AC07; and f. E. until a Registered Exchange Offer has been consummated or a Shelf Registration Statement has been filed and becomes effective with respect to the New Notes, the New Notes shall be subject to the transfer restrictions applicable to a registration rights agreement dated October 5Restricted Global Note or Restricted Definitive Note, 2018 relating to such Additional as applicable, and shall have a different CUSIP number than that of the Existing Notes, which shall be a “Registration Rights Agreement” for purposes under the Indenture.

Appears in 1 contract

Sources: Supplemental Indenture (Vanguard Health Systems Inc)

Terms of New Notes. The New Notes are to be issued as Additional Notes under the Indenture and pursuant to this Supplemental Indenture shall: a. A. be issued as part of the existing series of Existing Notes previously issued under the Indenture, Indenture and the New Notes and the Existing Notes shall be a single class for all purposes under the Indenture, including, without limitation, with respect to waivers, amendments, redemptions and offers to purchase; b. be issued at an issue price of 104.00%, plus accrued and unpaid interest from October 1, 2018 and will B. be issued on October 5March 30, 20182012 at a purchase price of 99.25% of the principal amount and will accrue interest from February 1, 2012; c. C. be issuable in whole in the form of one or more Global Notes to be issued in the name of Cede & Co. and held by the Trustee as Custodian for the Depositary Depository and in the form, including appropriate transfer restriction legends, provided in Exhibit 1 to the Appendix A1 and Exhibit A2, as applicable, to the Indenture; d. D. the New Notes shall initially bear, in the case of New Notes sold under Rule 144A of the Securities Act144A, the CUSIP number of ▇▇▇▇▇▇▇▇ and ISIN number of US665531AF68US92203PAJ57, and, in the case of New Notes sold under Regulation S of the Securities Act, initially bear the CUSIP number of ▇▇▇▇▇▇▇▇▇ U92165 AE6 and ISIN number of USU66499AC57; e. bear interest from October 1, 2018, with a first Interest Payment Date of January 1, 2019USU92165AE62; and f. E. until a Registered Exchange Offer has been consummated or a Shelf Registration Statement has been filed and becomes effective with respect to the New Notes, the New Notes shall be subject to the transfer restrictions applicable to a registration rights agreement dated October 5Restricted Global Note or Restricted Definitive Note, 2018 relating to such Additional as applicable, and shall have a different CUSIP number than that of the Existing Notes, which shall be a “Registration Rights Agreement” for purposes under the Indenture.

Appears in 1 contract

Sources: Supplemental Indenture (Vanguard Health Systems Inc)

Terms of New Notes. The New Notes are to be issued as Additional Notes under the Indenture and pursuant to this First Supplemental Indenture shall: a. A. be issued as part of the existing series of Existing Notes previously issued under the Indenture, Indenture and the New Notes and the Existing Notes shall be a single class for all purposes under the Indenture, including, without limitation, with respect to waivers, amendments, redemptions and offers to purchase; b. be issued at an issue price of 104.00%, plus accrued and unpaid interest from October 1, 2018 and will B. be issued on October 5March 14, 20182013 and will accrue interest from November 1, 2012; c. C. be issuable in whole in the form of one or more Global Notes to be issued in the name of Cede & Co. and held by the Trustee as Custodian for the Depositary DTC and in the form, including appropriate transfer restriction legends, provided in Exhibit 1 to the Appendix to A of the Indenture; d. bear, D. in the case of New Notes sold under Rule 144A of the Securities Act144A, bear the CUSIP number of ▇▇▇▇▇▇▇▇▇ 52736R BE1 and ISIN number of US665531AF68US52736RBE18, and, in the case of New Notes sold under Regulation S of the Securities Act, initially bear the CUSIP number of ▇▇▇▇▇▇▇▇▇ U52799 AY6 and ISIN number of USU66499AC57; e. bear interest from October 1, 2018, with a first Interest Payment Date of January 1, 2019USU52799AY66; and f. E. until a Registered Exchange Offer has been consummated or a Shelf Registration Statement has been filed and becomes effective with respect to the New Notes, the New Notes shall be subject to the transfer restrictions applicable to a registration rights agreement dated October 5, 2018 relating to such Additional Transfer Restricted Note and shall have a different CUSIP number than that of the Existing Notes, which shall be a “Registration Rights Agreement” for purposes under the Indenture.

Appears in 1 contract

Sources: First Supplemental Indenture (Levi Strauss & Co)